Coagulopathy Reversal in HCV Related Cirrhosis Patients

Mahmoud, Reem Abdalmonem; El Sherif, Ahmad Abdel Samie; Ghobrial, Ayman Gameel

doi:10.21608/mjmr.2023.220093.1435

	Coagulopathy Reversal in HCV Related Cirrhosis Patients
Minia Journal of Medical Research
Articles in Press, Accepted Manuscript, Available Online from 01 August 2023
Document Type: Original Article
DOI: 10.21608/mjmr.2023.220093.1435
View on SCiNiTO
Authors
Reem Abdalmonem Mahmoud ¹; Ahmad Abdel Samie El Sherif²; Ayman Gameel Ghobrial³
¹Minia university, faculty of medicine, clinical pathology department
²Clinical pathology, Faculty of Medicine, Minia University.
³Clinical pathology department, Faculty of medicine, Minia Univerisity
Abstract
Background: Cirrhosis is accompanied by haemostasis modifications. Cirrhotic individuals, show complicated coagulation alterations that comprise decreased hepatic synthesis of both pro- and anticoagulant elements as well as elevated concentrations of procoagulant agents synthesized outside the liver. According to current understanding, these modifications lead to a rebalanced but vulnerable coagulation system that can quickly tip into a hypercoagulable condition. Aim of the work: The research aimed to discuss the hypercoagulability in people having HCV related cirrhosis before and post-treatment using traditional worldwide and individual‐factor coagulation techniques. Subjects and Methods: 25 patients (14 male and 11 female) with HCV related cirrhosis, from 22 to 77 years old, subjected to coagulation tests PT, APTT, activity of PT %, INR, TAT, F1+ 2, and Protein C before and after releasing of the HCV with DAA, and 18 healthy individuals (11 male and 7 female) as a control group . Results: as the patients group post-treatment compared to the patients group before treatment there was statistically significant decrease in the PT test P= (0.008), APTT test, TAT test, and F1+2 test, while there was statistically significant increase of activity of PT % test with P=(0.01) . Conclusion: This study revealed improvement of hemostatic derangement in HCV related liver cirrhosis patients after 12 weeks of treatment with DAAs in the form of correction of routine coagulation tests (PT level, % of active PT test, APTT test), plus decrease of the markers of hypercoagulability (TAT test and F1+2 test) with no significant change in protein C level.
Keywords
PT; APTT; TAT; F1+2; Protein C


Statistics Article View: 35